second booster dose - versus first booster dose - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.22 [0.17, 0.28]< 10%1 study (-/1)100.0 %NAnot evaluable crucial-
deaths (time to event analysis only) 0.22 [0.17, 0.28]< 10%1 study (-/1)100.0 %NAnot evaluable crucial-
confirmed COVID (any severity) 0.55 [0.49, 0.62]< 194%5 studies (2/3)100.0 %NAnot evaluable important-
hospitalization 0.32 [0.25, 0.40]< 10%1 study (-/1)100.0 %NAnot evaluable important-
symptomatic Covid-19 0.45 [0.36, 0.57]< 169%4 studies (2/2)100.0 %NAnot evaluable important-
severe COVID-19 occurrence 0.35 [0.29, 0.42]< 10%2 studies (-/2)100.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.